| abstract |
Disclosed herein are GNGN and G1/G2 antibodies that recognize and bind various FcRs and C1 q. Also disclosed herein are glycan-optiminzed antibodies, predominantly of the GNGN or G 1 /G2 glycoform, with enhanced Fcγ receptor binding achieved through CHO, Nicotiana benthamiana and yeast manufacturing systems. Nucleic acids encoding these antibodies, as well as expression vectors and host cells including these nucleic acids are also disclosed herein. Methods and pharmaceutical compositions including the monoclonal antibodies are provided herein for the prevention and/or therapeutic treatment of viral infections, cancers and inflammatory diseases. |